Accéder au contenu
Merck

[Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia].

Terapevticheskii arkhiv (2012-12-21)
N N Sharkunov, T N Moiseyeva, E E Zybunova, O Yu Vinogradova, S K Kravchenko
RÉSUMÉ

To treat patients with different concurrent cancers, including lympho- and myeloproliferative neoplasms, is a difficult task. The paper presents the experience in successfully treating lymphogranulomatosis occurring in a female patient with chronic myeloid leukemia (CML). A combination of the BEACOPP-14 polychemotherapy regimen and imatinib induced no severe complications. Grade 2 neutropenia requiring no use of granulocyte colony-stimulating factors is the only manifestation of hematological toxicity. Infectious complications were successfully eliminated by first-line antimicrobial therapy in the intercourse periods. Remission in lymphogranulomatosis was achieved by polychemotherapy. The authors conclude that the chosen therapy option is effective and relatively safe in treating patients with CML concurrent with lymphogranulomatosis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Procarbazine hydrochloride, ≥98% (HPLC)